# Tirzepatide FAQ — Common Questions Answered

> Tirzepatide frequently asked questions: is it FDA approved, how does it work, weight loss results, side effects, difference from semaglutide, half-life, and more. Cited answers.

## Is tirzepatide FDA approved?

Yes. Tirzepatide received U.S. FDA approval for type 2 diabetes mellitus in May 2022. A second approval for chronic weight management in adults with obesity or overweight plus a weight-related condition followed in November 2023. A third approval for moderate-to-severe obstructive sleep apnea in adults with obesity has also been granted. It is not approved for type 1 diabetes [7, 8].

## How long has tirzepatide been around?

The compound was first described in the peer-reviewed literature in 2018 under its development code LY3298176, reporting the dual GIP/GLP-1 receptor design and Phase 1 data in 142 subjects [1]. Phase 3 trials began shortly after. The first FDA approval was in May 2022 — approximately four years from first publication to approval, a typical timeline for a novel drug with an expedited regulatory pathway.

## What are the drawbacks of tirzepatide?

The most significant drawbacks are gastrointestinal side effects — nausea, vomiting, diarrhoea, and constipation — which drive most treatment discontinuations and are especially frequent during dose escalation. A meta-analysis of nine trials found a significantly elevated composite gallbladder/biliary disease risk (RR 1.97) [6]. The prescribing information carries a boxed warning about thyroid C-cell tumours in rodents. Lean-mass loss alongside fat loss and weight regain after stopping are additional considerations [19, 22].

## Who cannot take tirzepatide?

The FDA prescribing information contra-indicates tirzepatide in people with a personal or family history of medullary thyroid carcinoma (a form of thyroid cancer) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) [7]. It is not approved for type 1 diabetes. People with a history of pancreatitis, severe gastrointestinal disease, or who are pregnant or breastfeeding should discuss with a physician before use. These are medical determinations; this site does not provide clinical advice.

## Does tirzepatide come in pill form?

No. The approved formulation of tirzepatide is a subcutaneous injection only — administered once weekly under the skin. An oral formulation has not been approved. The once-weekly injection schedule is enabled by the compound's approximately five-day elimination half-life, itself conferred by the fatty diacid modification of the peptide backbone [7, 10].

## What is tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide that activates two gut hormone receptors simultaneously: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). It was developed by Eli Lilly under the code LY3298176 and is the first FDA-approved dual incretin receptor agonist. It is prescribed for type 2 diabetes, chronic weight management, and obstructive sleep apnea [1, 7, 8].

## How does tirzepatide work?

Tirzepatide activates both the GIP and GLP-1 receptors — hormone receptors on pancreatic cells and in the brain and gut. GIP and GLP-1 are 'incretin' hormones (gut-derived hormones that boost insulin release after eating). By activating both, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. In vitro studies established it as an imbalanced, biased dual agonist favouring the GIP receptor [1, 5].

## What does tirzepatide do in the body?

In the body, tirzepatide: stimulates insulin secretion in proportion to blood glucose levels (limiting hypoglycaemia risk at therapeutic doses), suppresses glucagon to reduce liver glucose output, slows gastric emptying to blunt post-meal glucose rises, and reduces appetite signalling centrally. The net effect across the phase 3 programme was large reductions in both blood sugar and body weight, with the weight effect exceeding prior single-receptor incretin therapies [1, 2, 3].

## What is tirzepatide used for?

Tirzepatide has three FDA-approved indications: (1) type 2 diabetes mellitus in adults (approved May 2022); (2) chronic weight management in adults with obesity or overweight plus a weight-related condition (approved November 2023); and (3) moderate-to-severe obstructive sleep apnea in adults with obesity. The SURPASS programme established the type 2 diabetes evidence base and the SURMOUNT programme established the obesity evidence base [2, 3, 7].

## Is tirzepatide a GLP-1?

Tirzepatide activates the GLP-1 receptor, but it is not a selective GLP-1 receptor agonist — it simultaneously activates the GIP receptor. The clinical pharmacology literature characterises it as an imbalanced dual agonist that engages the GIP receptor more fully than the GLP-1 receptor, and exhibits biased GLP-1 receptor signalling favouring cAMP generation [5]. It is distinct from the GLP-1 receptor agonist class in mechanism, structure, and regulatory classification [8].

## How does tirzepatide work for weight loss?

In the obesity setting, tirzepatide reduces food intake through appetite suppression — a central effect of GIP and GLP-1 receptor agonism — and slows gastric emptying, which prolongs satiety after meals. In the SURMOUNT-1 trial, this translated to mean weight reductions of up to -20.9% over 72 weeks at the 15 mg dose [3]. The mechanism is not purely caloric — incretin receptor agonism also alters appetite-regulating circuitry in ways that are not fully characterised.

## How much weight can you lose on tirzepatide?

In SURMOUNT-1, adults with obesity without diabetes lost a mean -15.0% (5 mg), -19.5% (10 mg), or -20.9% (15 mg) of body weight over 72 weeks, versus -3.1% with placebo [3]. In SURMOUNT-5, adults treated at their maximum tolerated dose (10 or 15 mg) lost a mean -20.2% at 72 weeks, versus -13.7% for the semaglutide comparator [4]. Individual results varied substantially; not everyone reaches average trial outcomes.

## How long does it take for tirzepatide to work?

In the SURPASS-2 type 2 diabetes trial, statistically significant HbA1c reductions were evident by 12 weeks and continued to grow through the 40-week endpoint [2]. In the SURMOUNT-1 obesity trial, weight loss began early and accumulated progressively over 72 weeks, with the greatest incremental loss seen during the first 36 weeks as doses escalated [3]. Meaningful glycaemic effects typically emerge within weeks; the full weight-loss trajectory takes months to years.

## What are the side effects of tirzepatide?

The most common tirzepatide side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and decreased appetite. These are dose-related and most frequent during dose escalation, usually attenuating over time. The prescribing information also documents injection site reactions, a boxed warning for thyroid C-cell tumours (rodent data, human significance unclear), and an elevated risk of gallbladder or biliary disease in pooled trial data [6, 7]. The [tirzepatide side effects](/side-effects) page covers each in detail.

## What are the bad side effects of tirzepatide?

The most clinically significant tirzepatide side effects are: (1) gastrointestinal events severe enough to cause discontinuation — a meta-analysis vs dulaglutide found a 32% higher discontinuation rate due to adverse events [15]; (2) the elevated gallbladder/biliary disease composite (RR 1.97 in a nine-trial meta-analysis) [6]; and (3) the boxed warning for thyroid C-cell tumours from rodent carcinogenicity studies, which is the basis for the medullary thyroid carcinoma contraindication [7]. Lean-mass loss and weight regain after stopping are additional sustained concerns [19, 22].

## Does tirzepatide cause diarrhea?

Diarrhoea is among the most common adverse events documented in tirzepatide trials and post-market data. A FAERS pharmacovigilance analysis found diarrhoea was the second most frequently reported gastrointestinal adverse event (12.8%), with most events occurring within three months of starting treatment [14]. In the SURMOUNT-1 trial, diarrhoea occurred more frequently with tirzepatide than placebo and was most common during dose escalation [3].

## What is the difference between semaglutide and tirzepatide?

Semaglutide is a selective GLP-1 receptor agonist; tirzepatide activates both the GIP and the GLP-1 receptors. In direct comparisons, tirzepatide produced greater HbA1c and weight reductions: in SURPASS-2, tirzepatide was superior to semaglutide 1 mg at all three doses for HbA1c reduction [2]; in SURMOUNT-5, tirzepatide produced -20.2% versus -13.7% body weight change at maximum tolerated doses [4]. Both are once-weekly subcutaneous injections. Side-effect profiles overlap, with gastrointestinal adverse events predominating in both.

## Is tirzepatide better than semaglutide?

In the head-to-head SURPASS-2 and SURMOUNT-5 trials, tirzepatide produced statistically superior glycaemic and weight reductions compared with semaglutide at the doses studied [2, 4]. The 2026 ACP living clinical guideline placed both as conditional first-line recommendations for obesity, noting the need for shared decision-making on benefits, harms, access, and individual factors [11]. 'Better' depends on the individual's clinical context, tolerability, and access — medical determinations that belong with a physician.

## How long does tirzepatide stay in your system?

Tirzepatide has an elimination half-life of approximately five days [10]. That means it takes roughly five days for the body to clear half of a given dose, and approximately four to five half-lives (about 20–25 days) for most of the drug to clear after the last dose. This extended half-life — conferred by the fatty diacid arm's albumin-binding affinity — is what makes once-weekly dosing pharmacologically viable.

## What is the half-life of tirzepatide?

The elimination half-life of tirzepatide is approximately five days, as characterised in population pharmacokinetic analyses of phase 3 programme data [10]. This is substantially longer than the half-life of unmodified peptides (minutes to hours) and is conferred by the C20 fatty diacid modification, which binds albumin in the bloodstream and dramatically extends circulation time. The five-day half-life is the pharmacokinetic basis for the once-weekly dosing schedule.

## Is tirzepatide a peptide?

Yes. Tirzepatide is a synthetic peptide — a chain of 39 amino acids (the same type of building block found in proteins). Its backbone derives from the native GIP (glucose-dependent insulinotropic polypeptide) hormone sequence, modified to enable simultaneous GLP-1 receptor engagement. The fatty diacid arm at position 20 is added to extend its half-life; without this modification the peptide would be cleared from the body within hours [1, 10].

## Why am I not losing weight on tirzepatide?

In the SURMOUNT-1 trial, mean weight loss accumulated progressively over 72 weeks, with substantial individual variation around the trial averages [3]. Plateaus — periods of several weeks with little scale movement — were widely reported by participants and are considered a normal part of the weight-loss arc rather than treatment failure. Weight response also depends on dose achieved, dietary behaviour, metabolic rate, sleep, and other factors. Patients experiencing inadequate response should discuss dose, dietary factors, and expectations with their prescribing physician.

---

An independent regulatory reading desk — the tirzepatide approval and trial record, cited to source, with no clinical role held.